RxDoctor Payments DataLook up a doctor →

Tolga Tuncer

Hematology & Oncology · Kansas City, MONPI 1477749380

Payments from drug & device makers

$1,015,964in general payments, 2019–2025

Across 218 payments — averaging $4660.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Servier Bioinnovation$765K
  • Merck$136K
  • Exelixis Inc.$65K
  • Pfizer$22K
  • GT Medical Technologies, Inc$15K
  • E.r. Squibb & Sons, L.L.C.$8K
  • plus $5K from 13 others

What the payments were for

  • Speaking & faculty fees$2,60027%
  • Travel & lodging$2,24924%
  • Food & beverage$4,66549%
  • Education$180%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015,964 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$46,990
Medicare patients
120
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,629
Dexamethasone72$1,042
Levetiracetam24$742
Ondansetron Hcl65$443
Prochlorperazine Maleate19$364
Metformin Hcl12$206
Pantoprazole Sodium14$118
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21,664$7,62913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →